ArticleScientific reports2025
Synergistic chemo-photothermal therapy using doxorubicin-loaded gold nanorods for enhanced apoptosis in lung cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics.Discover oncology · 2026Article
- Mesoporous silica nanoparticles functionalized with folic acid and zinc for enhanced targeted delivery of daunorubicin to breast cancer cells.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the most lethal malignancies worldwide, largely due to late-stage detection, rapid progression, and resistance to conventional therapies. Although current modalities-surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy-have improved outcomes, long-term survival rates remain unsatisfactory. Photothermal therapy (PTT), which employs near-infrared (NIR) light to induce localized hyperthermia, has recently emerged as a promising complement to standard treatments by enhancing drug delivery and overcoming resistance. In this work, we investigated a combinatorial strategy using doxorubicin (DOX)-loaded gold nanorods functionalized with thiolated β-cyclodextrin (AuNRs@S-β-CD-DOX) in conjunction with 808 nm NIR laser irradiation in A549 human lung cancer cells. Apoptosis was evaluated through gene expression profiling, TUNEL assay, and Western blot analysis. Mechanistically, this triple approach activated both intrinsic (caspase-9) and extrinsic (caspase-8) apoptotic pathways, as evidenced by cleavage of procaspases and robust caspase-3 activation. Strikingly, the combined treatment (DOX 0.078 µM + AuNRs@S-β-CD + laser) induced apoptosis in nearly 60% of cells, far surpassing single or dual treatments, while operating at a DOX dose substantially below its IC50 value. The synergistic effect was attributed to enhanced intracellular DOX release mediated by AuNR photothermal heating and increased membrane permeability upon laser exposure. These findings demonstrate that AuNR-assisted chemo-photothermal therapy can overcome drug resistance and amplify apoptosis, providing a rational, targeted, and effective strategy for advancing lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.